EXHIBIT 31.1


       CERTIFICATIONS UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
       ------------------------------------------------------------------

I,   Jean-Luc Berger, certify that:


     1.  I have reviewed this annual report on Form 10-KSB of Kyto Biopharma,
         Inc.;


     2.  Based on my knowledge, this report does not contain any untrue
         statement of a material fact or omit to state a material fact necessary
         to make the statements made, in light of the circumstances under which
         such statements were made, not misleading with respect to the period
         covered by this report;


     3.  Based on my knowledge, the financial statements, and other financial
         information included in this report, fairly present in all material
         respects the financial condition, results of operations and cash flows
         of the registrant as of, and for, the periods presented in this report;


     4.  I am responsible for establishing and maintaining disclosure controls
         and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for
         the small business issuer and have:


         a) designed such disclosure controls and procedures to ensure that
         material information relating to the small business issuer, including
         its consolidated subsidiary, is made known to us by others within those
         entities, particularly during the period in which this report is being
         prepared;


         b) evaluated the effectiveness of the small business issuer's
         disclosure controls and procedures as of a date within 90 days prior to
         the filing date of this report (the "Evaluation Date"); and


         c) presented in this annual report our conclusions about the
         effectiveness of the disclosure controls and procedures based on our
         evaluation as of the Evaluation Date;


     5.  I have disclosed, based on our most recent evaluation, to the small
         business issuer's auditors and the audit committee of registrant's
         board of directors (or persons performing the equivalent function):


         a) all significant deficiencies in the design or operation of internal
         controls which could adversely affect the small business issuer 's
         ability to record, process, summarize and report financial data and
         have identified for the registrant's auditors any material weaknesses
         in internal controls; and


         b) any fraud, whether or not material, that involves management or
         other employees who have a significant role in the small business
         issuer's internal controls; and


     6.  I have indicated in this report whether or not there were significant
         changes in internal controls or in other factors that could
         significantly affect internal controls subsequent to the date of our
         most recent evaluation, including any corrective actions with regard to
         significant deficiencies and material weaknesses.


         Date:  June 27, 2005


         By:    /s/ Jean-Luc Berger
                ------------------------------------
                Jean-Luc Berger
                President, Chief Executive Officer
                and Acting Chief Financial Officer